Introduction
in increased parathyroid stimulation from each of the principal modulators, namely decreased calcium, In this review we discuss some of the clinical implicaincreased phosphate, and decreased calcitriol. This tions of progress in our understanding of the action of scenario is further complicated by the blunted target vitamin D and its derivatives on calcium, phosphate organ responsiveness to both PTH and calcitriol in homeostasis and skeletal function in uraemia.
uraemia. The parathyroid glands synthesize and secrete parathyroid hormone (PTH ) in response to low calcium, low 1,25-dihydroxyvitamin D 3 (calcitriol ), and high phosphate concentrations. The interplay between these The vitamin D receptor elements is complex, operating through several feedback mechanisms. Both PTH and calcitriol regulate Calcitriol mediates its genomic effects through the circulating calcium and phosphate concentrations vitamin D receptor ( VDR), which is a member of the through their action on target organs, namely the steroid/thyroid superfamily of nuclear receptors. kidney, bone, and intestine. PTH and calcitriol regulate Calcitriol binding to VDR results in changes in tranone another's production, and additionally are both scription rates for those genes that contain vitamin D regulated separately by extracellular calcium and phos-responsive elements ( VDREs). There are many other phate, as schematically illustrated in Figure 1 . The facets to this process, the details of which are beyond impairment of phosphate excretion and of calcitriol the scope of this review. Interested readers are directed to other reviews of this topic [1, 2] . Uraemia diminishes the tissue response to calcitriol and this is likely to be due, at least in part, to abnormal regulation and function of the VDR Recently, homozygous VDR knockout mice have been generated [7, 8] . These animals demonstrate phenotypic characteristics similar to that of clinical hypocalcaemic vitamin D-resistant rickets (HVDRR). Fig. 1 . The interrelationships between homeostatic hormones. When these mice are placed on a 'rescue diet', in which Augmentation and reduction of linked processes/concentrations are mineral ion homeostasis is 'normalized', they do not depicted as positive (+ve) or negative (−ve) respectively. *These develop hyperparathyroidism or the bone abnormalrelationships are qualitatively preserved in uraemia with the excepities observed in untreated animals [9] , suggesting that tion of PTH-driven phosphaturia. The absence of phosphaturia in ESRD results in PTH acting as a phosphataemic hormone, as part the major consequence of VDR ablation is the impairof a positive feedback loop with phosphate. ment of intestinal calcium absorption and mobilization of skeletal calcium.
Correspondence and offprint requests to: Dr J. Cunningham, For example, the presence or absence of a cleavage [18] , although this view is contradicted by others [19] .
In contrast to calcitriol, both calcium and phosphate site for the restriction enzyme BsmI in the 7th intron of the VDR gene confers a polymorphism that has regulate PTH production by post-transcriptional effects on pre-proPTH mRNA [20] . been linked to bone mineral density in renal patients [10] . The presence or absence of the restriction site Hyperphosphataemia predicts a poor outcome to vitamin D therapy and new data have shown a direct defines a 'b' or 'B' allele respectively. A relationship between serum intact PTH (iPTH ) concentrations and role for phosphate on PTH secretion [21] [22] [23] . In intact rat parathyroids incubated in culture, high phosphate genotypes was found in renal failure patients, with lower iPTH concentrations associated with a BB geno-(3-4 mmol/l ) concentrations were able to increase PTH secretion 3-4-fold above basal levels in a normal type [11] . However, studies that have tried to evaluate a physiological basis to explain the effect of VDR calcium environment and high phosphate concentrations also blunted the suppressive actions of calcium polymorphisms have so far been unsuccessful [12, 13] and it is not yet clear whether these polymorphisms on PTH secretion in this assay [23] . These data suggest that there is likely to be a mechanism whereby paraare of use in predicting an individual's responsiveness to calcitriol therapies.
thyroid cells 'sense' and respond to extracellular phosphate, presumably through a cell membrane system Rapid actions of calcitriol that could not be adequately explained by an effect on gene transcription that can mediate these signals. A possible candidate is the sodium-dependent phosphate co-transporter identihave been demonstrated. This has led to the postulation of a second vitamin D receptor, located in the plasma fied in rat parathyroid, termed rat PiT-1, which is regulated by calcitriol and shows close homology with membrane, that is able to transduce a signal from calcitriol independent of the genomic pathway the mouse and human PiT-1 type III sodium-phosphate cotransporters [24] . (reviewed in [14] ). This prompts speculation that the tissue specific selective actions of vitamin D metabolites could be the result of different effects on both the Parathyroid cell proliferation classical genomic ( VDR) and non-genomic receptors.
Although normal parathyroid tissue has a constitutively low basal cell proliferation rate [25] , a common feature of chronic renal failure is irreversible para-
Calcitriol and the parathyroids
thyroid hyperplasia [26 ] . The same factors that augment PTH secretion also modulate parathyroid PTH synthesis and secretion growth, namely low calcium, low calcitriol and high Calcitriol suppresses PTH directly by powerfully redu-phosphate [21, [27] [28] [29] . Calcitriol is a potent inhibitor cing PTH gene transcription [15] , as well as by several of proliferation and promoter of differentiation in other processes (Figure 2 ). This repression of PTH many cell types including parathyroid cells [30] and, transcription is mediated by a negative vitamin D in a uraemic animal model, calcitriol administration response element ( VDRE) in the gene promoter [16 ] . was shown to inhibit parathyroid proliferation [31] . The effects of calcium on the parathyroids are mediated These issues are of great clinical importance in that through a specific calcium sensing receptor (CaR) [17] the dynamics of parathyroid cell turnover are such which, in the rat, may be upregulated by calcitriol that hyperplasia can develop quite quickly, whereas apoptosis is exceedingly slow-effectively a one-way ticket.
Calcitriol and the kidney
PTH stimulated renal 1a-hydroxylation of 25-hydroxyvitamin D 3 to the active hormone is checked by a feedback inhibition, whereby calcitriol promotes its own degradation directly by suppressing 1a-hydroxylase and stimulating 24-hydroxylase activity, and indirectly by elevating ECF calcium. The 1a-hydroxylase gene has now been characterized and studies of its promoter region have identified positive regulatory regions for PTH and calcitonin and a negative regulatory region for calcitriol [32] , confirming earlier functional studies. Similar studies identified two VDREs in the upstream region of the 24-hydroxylase gene [33] . These data further corroborate at a molecular level the well-documented physiological role of calcitriol on these enzymes. been recently identified. Megalin, a multifunctional of bone to respond to such perturbations, partly because of blunted responses to PTH [38] . This bluntclearance receptor located on the luminal surface of proximal convoluted tubule (but not other tubular ing is partially corrected by provision of calcitriol and/or restriction of phosphate [39] . cells), is responsible for the delivery to the 1a-hydroxylase in the proximal tubule cells of the Maintenance of normal bone turnover in uraemia is an important goal. New vitamin D analogues and vitamin D binding protein/25(OH )D 3 complex which is filtered through the glomerulus [34] . These findings calcimimetics may allow us to achieve profound PTH suppression in a large number of patients, thereby are of great interest since they contradict the previous assumption that the substrate for renal 1a-hydroxylase removing a major stimulator of osteoblasts, potentially resulting in adynamic bone disorders. A useful property was free 25(OH )D 3 that diffused from ECF across the baso-lateral membrane into the proximal tubular cell, for a calcitriol surrogate in these circumstances would be to maintain osteoblast function by substituting for as well as raising the possibility that decreased GFR of any cause could reduce substrate delivery to the the anabolic effect of PTH, while potently suppressing the parathyroid. Few studies have examined this issue renal 1a-hydroxylase.
The role of calcitriol on calcium and phosphate specifically, although in one report the analogue 22-oxacalcitriol (OCT ) was shown to suppress PTH in regulation in the kidney has often been contradictory although most evidence points to conservation. the uraemic dog without increasing the risk of adynamic bone disease [40] . We have found that there are Calcitriol upregulates the mRNA and protein expression of the renal type II sodium-dependent phosphate differences in the ability of calcitriol analogues to stimulate production of the cytokine interleukin-6 transporter (NaPi-2) in the rat, increasing phosphate uptake in vitamin D deficient rats [35] . Furthermore, (IL-6) in human osteoblast-like cells ( Table 1 ). IL-6 is a paracrine factor that mediates osteoblast/osteoclast the human NaPi-3 gene, was shown to contain a calcitriol-sensitive VDRE in its promoter region [35] , signalling, and may be important in the recruitment of osteoclast progenitors. Maximum stimulation of pointing to a possible mechanism of calcitriol-mediated phosphate reabsorption in the kidney. However, in IL-6 production was achieved by calcitriol and 19-nor-1,25-dihydroxyvitamin D 2 (paricalcitol ) at another twist to this puzzle a recently identified phosphate-regulating gene with homology to neutral endo-fairly high concentrations-10−7-10−9 mol/l, whereas OCT and 1,25-dihydroxydihydrotachysterol 2 were peptidases (PHEX ) is also thought to affect calcitriolmediated phosphate absorption. PHEX, which is maximally active at much lower and therapeutically achievable concentrations-10−11-10−13 mol/l [41]. responsible for X-linked hypophosphataemic rickets ( XLH ), is postulated to inactivate a potent, still uncharacterized, circulating factor that has been named
Clinical developments
'phosphatonin'. Phosphatonin may play an important role in phosphate homeostasis by inhibiting both renal NaPi-2 and the renal 1a-hydroxylase [1] .
The drawbacks of calcitriol therapy (unwanted hypercalcaemia, hyperphosphataemia, inadequate parathyroid suppression, or parathyroid oversuppression)
Calcitriol and the intestine
were tackled first by novel, highly unphysiological regimens of calcitriol administration and more recently Pharmacokinetic issues may be important-the mat-with structurally modified calcitriol analogues uration cycle of small-bowel epithelial cells is in the ( Table 2) . order of 70 h, thereby setting a finite limit on the duration of effect of a pulsed dose of a vitamin D Current therapies analogue. Such considerations would not apply in, for
The principal therapies still used are calcitriol and its example, parathyroid or bone cells. The promotion of pro-drug, alfacalcidol. They appear to be equally intestinal calcium transport by calcitriol may be partly effective, regardless of dosing regimens. Fischer and non-genomic-a near instantaneous response has been Harris [42] found that in haemodialysis patients with observed in some studies-transcaltachia [36 ] and the postulated membrane receptor for calcitriol may be physiological demands. Uraemia may affect the ability 2°HPT there was no difference between intermittent Ca-BP9k in the intestine may help to explain the lower calcaemic activity of this agent [51] . However, despite oral or i.v. calcitriol regimens. Similar prospective trials in haemodialysis patients also report that the route of these encouraging data in animal models, clinical studies report that effective PTH suppression is still calcitriol administration confers no clinical benefit [43, 44] . In another randomized trial examining the accompanied by hypercalcaemia in many patients [52] .
Careful comparisons with calcitriol and/or alfacalcidol efficacy of pulse or daily oral calcitriol administration in CAPD patients, both modalities were equally effect-are awaited. ive at suppressing PTH [45] despite the higher peak concentrations achieved with the pulse regimen. The 1-alpha-hydroxy vitamin D 2 evidence from these and other controlled studies supIt had been assumed that the metabolism of vitamin port the view that there is probably little or no D 2 and vitamin D 3 with, respectively, the ergosterol difference between i.v. and oral administration, and cholesterol side-chain structure, led to the formaalthough it must be borne in mind that with i.v.
tion of similar 1,25-dihydroxyvitamin D metabolites, injection patient compliance is ensured [46 ] . but recent studies in man have suggested that this may not be the case [53, 54] . For example, alfacalcidol New analogues (1a-OH-D 3 ) is 25-hydroxylated to form calcitriol, whereas 1a-OH-D 2 is metabolized to both 1,25-Many vitamin D analogues have been developed outside the context of renal disease. It was shown in the dihydroxyvitamin D 2 and 1,24(S)-dihydroxyvitamin D 2
. The latter metabolite is a potent antiproliferative early 1980s that calcitriol has effects on cell proliferation and differentiation and many analogues have since agent with minimal calcaemic properties [53, 55] . Initial studies in haemodialysis patients have shown the been found to have much more potent antiproliferative properties. Many of these new analogues effectiveness of 1a-OH-D 2 in suppressing secondary hyperparathyroidism without causing hypercalcaemia are less calcaemic. For example, the anti-psoriasis drug calcipotriol [47] is 'non-calcaemic' because of its rapid and without recourse to adjusting the dose of calciumbased phosphate binders [56 ] . Early results from a catabolism once it penetrates the dermis. Other analogues have been shown to reduce circulating PTH large multicentre trial have also demonstrated the efficacy of this vitamin D metabolite in reducing severe concentrations with only modest effects on serum calcium and no hyperphosphataemia [48] , and some hyperparathyroidism [57] but, as with OCT, comparisons with calcitriol or alfacalcidol are still awaited. of these may find a use in the treatment of hyperparathyroid disorders. Figure 3 shows where it might be possible for an Paricalcitol analogue to differ from calcitriol and therefore potenParicalcitol (19-nor-1,25-dihydroxyvitamin D 2 ) has tially vary the response. This may in turn lead to either also shown encouraging results as a calcitriol alternatreduced or enhanced expression of proteins involved ive. This compound was found to suppress parathyroid in calcium and phosphate homeostasis and/or alter gland secretion and growth in the uraemic rat model cellular functions.
[58,59]. Of interest was an observed lack of intestinal VDR upregulation that was seen in the calcitriol-
22-oxacalcitriol (OCT)
treated group [59] . This lack of effect in the intestine may account for the reduced calcaemic and phosphata-OCT was developed in the late 1980s and was shown to suppress PTH secretion and synthesis in vitro and emic action of this analogue in that model. In recently published clinical studies, paricalcitol was found to in vivo [49] while eliciting much less calcaemia than calcitriol. This encouraging selectivity of OCT may be have good PTH suppression with very few and only transient increases in serum calcium in haemodialysis the result of differences in action at different target tissues. OCT, in contrast to the sustained action of patients [60, 61] . However, preliminary reports of comparisons with calcitriol suggest that there is probably calcitriol, stimulated only transient intestinal calcium absorption in a rat model [50] . More recent evidence little difference between paricalcitol and calcitriol in haemodialysis patients. also suggests that the lack of effect of OCT on intestinal 
Falecalcitriol
reminiscent of alfacalcidol and calcitriol ) is important, as is refinement of the dosing regimens for the newer This fluorinated calcitriol analogue has been compared analogues. with alfacalcidol [62] and in a crossover study demonstrated better PTH suppression, but also more hyper-Acknowledgements. N. J. Schroeder was supported by grants from calcaemia than alfacalcidol. 1997; 16: 391-396 and the clinical studies (significant calcaemic effects
